GlassScriptPhysician profile
Muralidhar Kannan
NPI 1275760464
$1,465.68
in general payments reported to CMS, 2019-2025
12 companies · $49.98 in 2025
The $49.98 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.64 · 2020: $75.42 · 2021: $96.97 · 2022: $315 · 2023: $435 · 2024: $460 · 2025: $49.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $457.74 | 2020-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $192.84 | 2020-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $136.64 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.29 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $129.15 | 2020-2024 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $120.34 | 2021-2023 | Lybalvi |
| Indivior INC. | $100.34 | 2023-2024 | Perseris |
| Abbvie INC. | $93.98 | 2022-2024 | |
| Allergan, INC. | $32.94 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $22.42 | 2024 | Cobenfy |
| Lundbeck LLC | $21.90 | 2024 | Abilify Asimtufii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muralidhar Kannan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.